Examples of using Tasimelteon in English and their translations into Swedish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
The active substance in HETLIOZ, tasimelteon, is able to act as a time-keeper for the body rhythms and resets them each day.
Treatment with tasimelteon resulted in a significant improvement, compared with placebo,
The most abundant metabolites of tasimelteon have less than one- tenth of the binding affinity of the parent molecule for both the MT1 and MT2 receptors.
that was designed to evaluate the maintenance of efficacy of tasimelteon after 12-weeks.
Metabolism of tasimelteon consists primarily of oxidation at multiple sites
When administered with a high-fat meal, the Cmax of tasimelteon was 44% lower than when administered in a fasted state, and the median Tmax was delayed by approximately 1.75 hours.
In pregnant rabbits administered tasimelteon during the period of organogenesis,
In animal studies, administration of tasimelteon during pregnancy resulted in developmental toxicity(embryofoetal mortality,
was co-administered with a 20 mg dose of tasimelteon.
drunk, alertness/drowsiness, balance platform test), there was a trend towards greater effects of tasimelteon plus ethanol versus ethanol alone, but the effects were not deemed significant.
were randomised to receive tasimelteon 20 mg or placebo, one hour prior to bedtime, at the same time every night for up to 6 months.
Use of tasimelteon should be avoided in combination with rifampin
Patients treated with tasimelteon experienced an overall improvement in clinical global functioning(CGI- C 2.6)
continue daily treatment with tasimelteon 20 mg for 8 weeks.
After taking tasimelteon, patients should limit their activity to preparing to go to bed
Tasimelteon exhibits a greater affinity for the MT2 as compared to the MT1 receptor.
Tasimelteon functions as a DMRA at the MT1 and MT2 receptors.
Tasimelteon may cause somnolence.
The effectiveness of tasimelteon to improve clinical global functioning was evaluated in SET.
The observed mean elimination half-life for tasimelteon is 1.3± 0.4 hours.